Russell Investments Group Ltd. Grows Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Russell Investments Group Ltd. raised its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 4,810.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 35,745 shares of the company’s stock after purchasing an additional 35,017 shares during the period. Russell Investments Group Ltd.’s holdings in Nurix Therapeutics were worth $673,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. US Bancorp DE increased its position in shares of Nurix Therapeutics by 144.7% during the 4th quarter. US Bancorp DE now owns 1,424 shares of the company’s stock valued at $27,000 after purchasing an additional 842 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in Nurix Therapeutics during the fourth quarter worth $209,000. EntryPoint Capital LLC purchased a new stake in shares of Nurix Therapeutics in the fourth quarter valued at $266,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Nurix Therapeutics by 21.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 15,020 shares of the company’s stock valued at $283,000 after acquiring an additional 2,632 shares during the period. Finally, Teacher Retirement System of Texas lifted its holdings in shares of Nurix Therapeutics by 18.4% in the 4th quarter. Teacher Retirement System of Texas now owns 16,263 shares of the company’s stock worth $306,000 after acquiring an additional 2,532 shares during the last quarter.

Insiders Place Their Bets

In other news, CFO Houte Hans Van sold 5,825 shares of Nurix Therapeutics stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $14.49, for a total value of $84,404.25. Following the transaction, the chief financial officer now owns 33,724 shares of the company’s stock, valued at $488,660.76. The trade was a 14.73 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Gwenn Hansen sold 3,690 shares of the stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $73,246.50. Following the sale, the insider now directly owns 55,937 shares of the company’s stock, valued at $1,110,349.45. The trade was a 6.19 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 12,326 shares of company stock worth $213,449. 7.40% of the stock is owned by corporate insiders.

Nurix Therapeutics Stock Up 8.6 %

Shares of NRIX stock opened at $11.46 on Wednesday. The firm has a market cap of $873.66 million, a price-to-earnings ratio of -3.97 and a beta of 2.23. Nurix Therapeutics, Inc. has a 52-week low of $8.18 and a 52-week high of $29.56. The company’s 50 day moving average is $12.93 and its 200 day moving average is $18.60.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.05. The business had revenue of $18.45 million for the quarter, compared to the consensus estimate of $12.78 million. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. During the same period last year, the business posted ($0.76) EPS. Analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on NRIX shares. Stifel Nicolaus cut their price target on shares of Nurix Therapeutics from $36.00 to $35.00 and set a “buy” rating on the stock in a report on Wednesday, April 9th. HC Wainwright reaffirmed a “buy” rating and set a $36.00 target price on shares of Nurix Therapeutics in a research note on Wednesday, April 2nd. Morgan Stanley raised their price target on Nurix Therapeutics from $16.00 to $17.00 and gave the stock an “equal weight” rating in a research note on Monday, February 3rd. Royal Bank of Canada upped their price objective on Nurix Therapeutics from $26.00 to $27.00 and gave the company an “outperform” rating in a research report on Wednesday, January 29th. Finally, Stephens reiterated an “overweight” rating and issued a $31.00 target price on shares of Nurix Therapeutics in a research note on Tuesday, January 21st. Three analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, Nurix Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $30.44.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.